Processa Pharmaceuticals, Inc. · NASDAQ:PCSA
Processa Pharmaceuticals — Investor Presentation (February 2024)
16 slides from Processa Pharmaceuticals's investor presentation, Feb 21, 2024
Slide 1: Next Generation Chemotherapy: Improved Treatment for More Patients
@ Processa Pharmaceuticals Next Generation Chemotherapy: Improved Treatment for More Patients Corporate Presentation February 2024
Slide 2: Forward Looking Statement and Disclosures
Forward Looking Statement and Disclosures @ rrocessa Pharmaceuticals This presentation includes forward-looking statements based upon our current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predi
Slide 3: About Processa Pharmaceuticals
About Processa Pharmaceuticals @ vrocessa Pharmaceuticals Next-Generation Chemotherapies (NGCs) Designed to Improve Survival and Quality of Life for Cancer Patients * Ade-risked strategy of developing new chemical entities (NCEs) based on improving pharmacokinetics of existing, proven treatments Pro
Slide 4: Processa Senior Management
Processa Senior Management George Ng Chief Executive Officer Joined Processa 2023, Former Roles: + President, COO, & Director, Calidi Biotherapeutics + Partner, PENG Life Science Ventures + Founder and President, Scilex Pharmaceuticals + JD, University of Notre Dame; B.A.S. Dual Degree, University o
Slide 5: Oncology Opportunity
Oncology Opportunity @ Processa Pharmaceuticals * More than 200,000 new cancer diagnoses worldwide across multiple indications for each NGC in development f > ys }: @— * NGC compounds will potentially address efficacy and toxicity at a a an optimized dose to show improvement over standard of care &
Slide 6: Processa's Pipeline
Processa’s Pipeline Drug Next Generation Capecitabine (Pcs6422) Next Generation Gemcitabine (Pcs3117) Next Generation Irinotecan (PCS11T) NASDAQ: PCSA Next Generation Cancer Indications Breast, Colorectal, Hepatocellular, Pancreatic, Gastric, & Other Solid Tumor Cancers Pancreatic, Gall Bladder, Non
Slide 7: How Our Oncology Assets Differ from Current Chemotherapy
Capecitabine — Low treatment response with high side effect profile Gemcitabine —High drug resistance and/or acquired resistance; administered as IV lrinotecan — Significant side-effect profile limits dosing and drug use NASDAQ: PCSA @ Processa Pharmaceuticals How Our Oncology Assets Differ from Cur
Slide 8: PCS6422 / Next Generation Capecitabine (NGC-Cap)
PCS6422 / Next Generation Capecitabine @ Processa Pharmaceuticals (NGC-Cap) ¢ Alters metabolism to increase distribution of 5-FU and cancer-killing molecules to cancer cells while reducing the metabolites that only cause side effects eiiteery * Active molecule same as Capecitabine but provides impro
Slide 9: NGC-Cap is Not the Same Treatment or Drug as FDA-Approved Capecitabine
NGC-Cap is Not the Same Treatment or Drug as @ Processa Pharmaceuticals FDA-Approved Capecitabine Capecitabine (Xeloda*) NGC-Cap ~ 80% - 90% to Anabolites ~ 10% - 20% to Anabolites Formation of, FBAL Related ~ 75% - 85% to FBAL Catabolite ‘ai Catabolites — Side Effects (e.g, HFS) = | Temporary’ & De
Slide 10: PCS3117 / Next Generation Gemcitabine (NGC-Gem)
PCS3117 / Next Generation Gemcitabine (NGC-Gem) Oral Drug with Same MOA as Gemcitabine * Provides improved treatment over Gemcitabine seen in previous pancreatic Efficacy cancer trial data; cancer cells exposed to more NGC-Gem cancer-killing molecules given more activating enzyme @ Processa Pharmace
Slide 11: NGC-Gem (Oral): Increase Metabolism to Cancer-Killing Molecules
NGC-Gem (Oral): Increase Metabolism to Cancer-Killing Active Cancer Killing Molecules NGC-Gem Adminteraton inSome Cancers UCK2 Expression >> dCK Expression Resulting in Metabolism to More Cancer- Killing Molecules for NGC-Gem than Gem Gemcitabine or Acquire Resistance NASDAQ: PCSA at PRM 55% - 85% o
Slide 12: PCS11T / Next Generation Irinotecan (NGC-Iri)
PCS11T / Next Generation Irinotecan @ Processa Pharmaceuticals (NGC-Iri) + Active molecule SN-38 is same active molecule in Irinotecan Efficacy * Distributes SN-38 differently, entering the cell membrane of cancer cells preferentially over normal cells, improving cancer-killing effect * Given MNM-SN
Slide 13: Tumor-Bearing Mice Had 200x Higher Drug In Tumor vs Muscle
Tumor-Bearing Mice Had 200x Higher Drug In Tumor vs Muscle Compared To 15x With Irinotecan ttt [Tumor/muscle=200 | SN-38, n6/s NGC-Iri NGC-Iri Irinotecan Irinotecan auc | Tumor/Tissue | auc | Tumor/Tissue Tissue | (ng/e*hr) Ratti (ng/g*hr) Ratio Tumor 3,855 1 1,153 1 Plasma 408 9.57 172 6.7 NASDAQ:
Slide 14: Summary of Activities/Milestones
Summary of Activities/Milestones @ vrocessa Pharmaceuticals fiero tibiiacbid NGC-Cap: Cohort review committee meeting to determine if Phase 1B MTD trial enrollment January 2024 V completed NGC-Cap: Finish defining regulatory paths to approval and ODR Phase 2 design based on FDA 102024 communications
Slide 15: Company Summary
Company Summary Compan' Strategic transition to oncology- focused company: Track record of drug development through regulatory approval: Innovative clinical development programs addressing issues with standard of care: Strong financial position to support progress: NASDAQ: PCSA Po: ioned foi ccess M
Slide 16: Investor & Media Relations
BZ Processa Pharmaceuticals Investor & Media Relations: CORE IR IR@processapharma.com NASDAQ: PCSA
Processa Pharmaceuticals — Investor Presentation (February 2024) on 6ix